Log in

Magenta Therapeutics Stock Forecast, Price & News

-0.31 (-3.86 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $7.72
50-Day Range
MA: $7.15
52-Week Range
Now: $7.72
Volume773,658 shs
Average Volume233,355 shs
Market Capitalization$372.51 million
P/E RatioN/A
Dividend YieldN/A
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Magenta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.92 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MGTA



Sales & Book Value

Annual SalesN/A
Book Value$3.62 per share


Net Income$-76,770,000.00


Market Cap$372.51 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
-0.31 (-3.86 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

How has Magenta Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGTA stock has decreased by 15.7% and is now trading at $7.72.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Magenta Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Magenta Therapeutics

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Magenta Therapeutics

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics Inc (NASDAQ:MGTA) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.06.
View Magenta Therapeutics' earnings history

What price target have analysts set for MGTA?

4 equities research analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.00 in the next year. This suggests a possible upside of 146.1% from the stock's current price.
View analysts' price targets for Magenta Therapeutics

Are investors shorting Magenta Therapeutics?

Magenta Therapeutics saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,550,000 shares, an increase of 13.1% from the July 30th total of 1,370,000 shares. Based on an average daily trading volume, of 323,300 shares, the short-interest ratio is currently 4.8 days. Approximately 5.3% of the shares of the stock are short sold.
View Magenta Therapeutics' Short Interest

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Myovant Sciences (MYOV), NVIDIA (NVDA), ADMA Biologics (ADMA), Nabriva Therapeutics (NBRV), Amarin (AMRN), Canopy Growth (CGC) and Crispr Therapeutics (CRSP).

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
  • Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
  • Ms. Alison Lawton, Board Advisor (Age 58)
  • Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
  • Ms. Manisha Pai, VP of Investor Relations & Communications

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (8.98%), Artal Group S.A. (0.93%), Luminus Management LLC (0.74%), Platinum Investment Management Ltd. (0.61%), Asymmetry Capital Management L.P. (0.53%) and Tekla Capital Management LLC (0.40%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke.
View institutional ownership trends for Magenta Therapeutics

Which institutional investors are selling Magenta Therapeutics stock?

MGTA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Ensign Peak Advisors Inc, Marshall Wace North America L.P., FMR LLC, FMR LLC, Platinum Investment Management Ltd., New York State Common Retirement Fund, and Bailard Inc.. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke.
View insider buying and selling activity for Magenta Therapeutics

Which institutional investors are buying Magenta Therapeutics stock?

MGTA stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Luminus Management LLC, Gilder Gagnon Howe & Co. LLC, Asymmetry Capital Management L.P., Tekla Capital Management LLC, Prosight Management LP, Marshall Wace LLP, and Monashee Investment Management LLC.
View insider buying and selling activity for Magenta Therapeutics

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $7.72.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $372.51 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.